Full Press Release Details
This presentation does not constitute an offering of any securities for sale or a solicitation
of offers to purchase securities. The Company's securities may not be offered or sold
under applicable securities laws or an exemption from registration. Any
public offering of the securities of the Company will be made by means of a prospectus
that will contain detailed information about the offering and the Company.
Under the Private Securities Litigation Reform Act of 1995: This release includes
forward-looking statements that reflect ONI BioPharma's current views with respect to
future events and financial performance.
These forward-looking statements are based
on management's beliefs and assumptions and information currently available. The
words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely
to historical matters identify forward-looking
statements. Investors should be cautious in relying on forward-looking statements
because they are subject to a variety of risks, uncertainties, and other factors that could
cause actual results to
differ materially from those expressed in any such forward-
looking statements. These factors include: future costs associated with any potential
listing sponsor, those factors set forth in our most recently filed annual report on Form
quarterly report on Form 10-Q, and other factors detailed from time to time
in filings with the Securities and Exchange Commission. We expressly disclaim any
responsibility to update forward-looking
ONI BioPharma is a multi-faceted biopharmaceutical
company with operations in four divisions:
ONI is commercializing its first consumer products:
, the first full-care oral probiotic that promotes healthy teeth and gums and whitens teeth
and freshens breath.
for weight loss is in clinical trials and, if successful, should be ready for marketing in 2009.
ONI expects to generate revenue from consumer products in 2009 both in the US and internationally.
Proceeds will support the Company s diagnostic, replacement therapy, and antibiotic divisions.
Patents, strategic sales channels, and international partners will support ONI s growth. ONI is developing
commercial and research facilities in Mexico and France to support its global strategy. ONI was
in 1996 by Dr. Jeffrey Hillman, a recognized expert in molecular genetics. The Company is based in
Financial Highlights
NYSE Alternext Paris: ALONI
Industry: Biopharmaceutical
Equity Cap: $13.03M (US)
Shares Outstanding: 38.3M
Four Product Divisions
DPOLT/Antibiotics Platform
ONI s science has developed into four distinct categories.
Technologies complement one another. ONI intends to use revenue
generated by initial consumer products to support research and
of longer-term therapies.
Mixture of 3 natural beneficial oral
Maintaining dental (tooth) health
Maintaining periodontal (gum) health
Promoting fresh breath
Safety and activity established in animals
Novel MOA - selectively kills white fat cells
Strong evidence for safety in humans
Clinical trial in Q2
LPT3-04 : Weight Loss Agent
Novel mechanism of action
Safe and very active in pilot studies
Most other gram positive infections
Mtb, both growing and dormant
No evidence for development of resistance
Hard to make by conventional fermentation
MU1140 - A Focus Techno
Platform for organic synthesis of MU1140
Proof of principle completed
Cost effective GMP production
Can make analogues of MU1140 and the other 50 known
Fast, sensitive, superior method for identification of targets for
new diagnostics, vaccines and drugs
Also applicable to various other problems such as
bioscavenging and biofouling
IVIAT / CMAT A Focus
Genetically modified Streptococcus mutans
One-time treatment for lifelong protection against most tooth
Strategy and Forecasted
Calendar of Development
* Consumer Health revenue is expected to support the growth of other business units.
15 projects completed
Second Phase I clinical trial
Commercially Available:
Regulatory approval &
marketing Evora & LPT3-04
in Europe, Asia, South America
Phase II/III clinical trial
Projected Summary Timeline
Benefits/Characteristics:
GRAS Generally Recognized as Safe status (vs FDA approval)
Significantly reduces regulatory costs
Faster generation of gross and net revenues
Lower capital requirements
Marketed in US and internationally (Mexico in early 2009)
Sales and marketing arrangements in place
Human and companion animal applications
ProBiora3 Finish identity work & mass
market companion pet product
Commence marketing upon granting of
regulatory exemption status non-US
Finish all clinical trials
Begin selling LPT3-04
Begin seeking regulatory exemptions in
non-US markets (Europe, Asia & South
Begin global marketing
ProBiora3 - Probiotic mint to promote gum and dental health.